RGD Reference Report - The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. - Rat Genome Database

RGD Reference Report - The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

General

The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.
Authors:	Thacker, SG Berthier, CC Mattinzoli, D Rastaldi, MP Kretzler, M Kaplan, MJ
Citation:	Thacker SG, etal., J Immunol. 2010 Oct 1;185(7):4457-69. Epub 2010 Aug 30.
RGD ID:	6906963
Pubmed:	PMID:20805419 (View Abstract at PubMed)
PMCID:	PMC2978924 (View Article at PubMed Central)
DOI:	DOI:10.4049/jimmunol.1001782 (Journal Full-text)
Systemic lupus erythematosus (SLE) is characterized by increased vascular risk due to premature atherosclerosis independent of traditional risk factors. We previously proposed that IFN-alpha plays a crucial role in premature vascular damage in SLE. IFN-alpha alters the balance between endothelial cell apoptosis and vascular repair mediated by endothelial progenitor cells (EPCs) and myeloid circulating angiogenic cells (CACs). In this study, we demonstrate that IFN-alpha promotes an antiangiogenic signature in SLE and control EPCs/CACs, characterized by transcriptional repression of IL-1alpha and beta, IL-1R1, and vascular endothelial growth factor A, and upregulation of IL-1R antagonist and the decoy receptor IL-1R2. IL-1beta promotes significant improvement in the functional capacity of lupus EPCs/CACs, therefore abrogating the deleterious effects of IFN-alpha. The beneficial effects from IL-1 are mediated, at least in part, by increases in EPC/CAC proliferation, by decreases in EPC/CAC apoptosis, and by preventing the skewing of CACs toward nonangiogenic pathways. IFN-alpha induces STAT2 and 6 phosphorylation in EPCs/CACs, and JAK inhibition abrogates the transcriptional antiangiogenic changes induced by IFN-alpha in these cells. Immunohistochemistry of renal biopsies from patients with lupus nephritis, but not anti-neutrophil cytoplasmic Ab-positive vasculitis, showed this pathway to be operational in vivo, with increased IL-1R antagonist, downregulation of vascular endothelial growth factor A, and glomerular and blood vessel decreased capillary density, compared with controls. Our study introduces a novel putative pathway by which type I IFNs may interfere with vascular repair in SLE through repression of IL-1-dependent pathways. This could promote atherosclerosis and loss of renal function in this disease.

Only show annotations with direct experimental evidence (0 objects hidden)

Object Symbol	Species	Term	Qualifier	Evidence	With	Notes	Source	Original Reference(s)
IL1RN	Human	systemic lupus erythematosus		IEP		protein:increased expression:plasma (human)	RGD
Il1rn	Rat	systemic lupus erythematosus		ISO	IL1RN (Homo sapiens)	protein:increased expression:plasma (human)	RGD
Il1rn	Mouse	systemic lupus erythematosus		ISO	IL1RN (Homo sapiens)	protein:increased expression:plasma (human)	RGD

Genes (Rattus norvegicus)


Il1rn (interleukin 1 receptor antagonist)

Genes (Mus musculus)


Il1rn (interleukin 1 receptor antagonist)

Genes (Homo sapiens)


IL1RN (interleukin 1 receptor antagonist)